Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.
Saved in:
| Title: | Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. |
|---|---|
| Authors: | Kilic IB; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Weberova P; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., VanDyke D; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Sirova M; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Kubesova K; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Fabilane CS; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Program in Molecular Biophysics, Johns Hopkins University, Baltimore, Maryland, USA., Mazhara V; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Liu K; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Behalova K; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Ptacek B; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Rihova B; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Spangler JB; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Kovar M; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic makovar@biomed.cas.cz. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Aug 11; Vol. 13 (8). Date of Electronic Publication: 2025 Aug 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
